Adamas Pharmaceuticals Inc (ADMS) Stock Price & Overview
NASDAQ:ADMS
Current stock price
The current stock price of ADMS is 8.22 null. Today ADMS is up by 0.74%. In the past month the price increased by 1.86%. In the past year, price increased by 84.72%.
ADMS Key Statistics
- Market Cap
- 374.98M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.02
- Dividend Yield
- N/A
ADMS Stock Performance
ADMS Stock Chart
ADMS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ADMS. When comparing the yearly performance of all stocks, ADMS is one of the better performing stocks in the market, outperforming 97.7% of all stocks.
ADMS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ADMS. ADMS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ADMS Earnings
ADMS Forecast & Estimates
14 analysts have analysed ADMS and the average price target is 8.69 null. This implies a price increase of 5.72% is expected in the next year compared to the current price of 8.22.
For the next year, analysts expect an EPS growth of 48.66% and a revenue growth 26.58% for ADMS
ADMS Groups
Sector & Classification
ADMS Financial Highlights
Over the last trailing twelve months ADMS reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 46.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -71.1% | ||
| ROA | -43.55% | ||
| ROE | N/A | ||
| Debt/Equity | -5.76 |
ADMS Ownership
ADMS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.9 | 364.65B | ||
| AMGN | AMGEN INC | 15.33 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.96 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.63 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.77 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.7 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.41 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.64 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.89 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADMS
Company Profile
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. The company is headquartered in Emeryville, California and currently employs 138 full-time employees. The company went IPO on 2014-04-10. The firm is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.
Company Info
IPO: 2014-04-10
Adamas Pharmaceuticals Inc
1900 Powell St Ste 1000
Emeryville CALIFORNIA 94608 US
CEO: Neil F. McFarlane
Employees: 138
Phone: 15104503554.0
Adamas Pharmaceuticals Inc / ADMS FAQ
What does ADMS do?
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. The company is headquartered in Emeryville, California and currently employs 138 full-time employees. The company went IPO on 2014-04-10. The firm is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.
What is the current price of ADMS stock?
The current stock price of ADMS is 8.22 null. The price increased by 0.74% in the last trading session.
Does ADMS stock pay dividends?
ADMS does not pay a dividend.
What is the ChartMill rating of Adamas Pharmaceuticals Inc stock?
ADMS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is ADMS stock listed?
ADMS stock is listed on the Nasdaq exchange.
Is Adamas Pharmaceuticals Inc (ADMS) expected to grow?
The Revenue of Adamas Pharmaceuticals Inc (ADMS) is expected to grow by 26.58% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is Adamas Pharmaceuticals Inc worth?
Adamas Pharmaceuticals Inc (ADMS) has a market capitalization of 374.98M null. This makes ADMS a Small Cap stock.